ArticleBlood2020

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.

Jordan Gauthier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.